Citations

Clear

16280 citation(s) found for "Yu, David".

(012) USE OF REAR TIP EXTENDERS IS ASSOCIATED WITH INCREASED RISK OF POST-OPERATIVE COMPLICATIONS AND PENILE PROSTHESIS REVISION IN PATIENTS UNDERGOING PRIMARY INFLATABLE PENILE PROSTHESIS PLACEMENT: RESULTS FROM A LARGE MULTI-INSTITUTIONAL COLLABORATIVE
Dalimov, Zafardjan , Ivan, SJ, Barham, David , Sadeghi‐Nejad, Hossein , Modgi, V, Andrianne, Robert, Sempels, Maxime, Hsieh, Tung‐Chin , Hatzichristodoulou, Georgios , Osmonov, Daniar , Lentz, A, Perito, Paul , Hotaling, James M. , Park, SH, Ziegelmann, Matthew , Pearce, Ian , Gross, MS, Yafi, FA, Simhan, J, Hammad, Muhammed , Hammad, Muhammed A M , Ivan, SJ, Hammad, M, Lentz, A, Renterghem, Koenraad van , Simhan, Jay

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.010 Get It

Abstract Introduction The utilization of rear tip extenders (RTE) is often imperative during Inflatable Penile Prosthesis (IPP) placement. The impact of RTE on perioperative morbidity of IPP surgery is underexplored. Objective In this study, we assess intraoperative and postoperative outcomes among patients undergoing primary IPP implantation with or without RTE. Methods We performed a multicenter, retrospective analysis of men undergoing primary IPP placement between July 2016 and July 2021. A total of 4308 patients were identified, of which 2963 had no RTE and 1345 had RTE. After 1:1 propensity score matching for all confounding variables, 840 patients without RTE were compared to patients with RTE for intraoperative and postoperative outcomes. Chi-square and Mann–Whitney tests were used for statistical analysis for categorial and continuous variables respectively. For multivariable analysis, we used a forward stepwise model and included significant variables found on preoperative characteristics of patients. Kaplan–Meier time to event analysis were compared with Mantel-Cox log-rank test. Results Patients with RTE use had more postoperative complications (9.6% vs 5.2%, p < 0.001). More specifically, RTE patients had more episodes of postoperative hematoma and bleeding (2.0% vs 0.7%, p = 0.033), device malfunction (2.7% vs 1.8%, p = 0.006), and glans-related complications (0.8% vs 0, p = 0.015). On multivariable analysis, use of RTE (OR 1.58, 95% CI 1.07-2.34, p = 0.021), AMS 700 series device (OR 1.93, 95% CI 1.27-2.94, p = 0.002), penoscrotal approach (OR 2.60, 95% CI 1.61-4.18, p < 0.001), and older age (OR 1.02, 95% CI 1.00-1.04, p = 0.035) were associated with increased risk of postoperative complications. Patients with RTE use had increased rate of postoperative IPP revision (5.0% vs 2.1%, p = 0.002). The use of RTE (OR 1.71, 95% CI 1.00-2.90, p = 0.046), AMS 700 series device (OR 1.73, 95% CI 1.01-2.97, p = 0.048), penoscrotal approach (OR 3.16, 95% CI 1.63-6.17, p < 0.001), and history of Peyronie’s disease (OR 2.24, 95% CI 1.31-3.82, p = 0.003) were associated with increased risk of postoperative IPP revision or explantation. On Kaplan–Meier analysis, use of RTE was associated with increased risk of postoperative complications and IPP revision or explantation within 48 months (log rank p = 0.001 and p = 0.002 respectively). Conclusions In this large multi-institutional cohort, patients with RTE experienced more hematoma, device malfunctioning, and glans related post operative complications. The use of RTE is an independent predictor of post-operative complications and IPP revision or explanation. Disclosure No.
Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders
Darakjian, Ashley A. , Bhutani, Mira, Fairweather, DeLisa , Kocsis, S , Fliess, Jessica J. , Khatib, Sami , Weigel, Gabe J , McCabe, Elizabeth J , Balamurugan, Varsini, Perona, Evan E , Gehin, Jessica M. , Jain, Angita , Sledge, Hanna, Hodge, David O. , Rozen, Todd D. , Soyer, Ozan, Cheung, Joseph , Shirey, David, Gajarawala, Shilpa , Munipalli, Bala , Weigel, G. , Kocsis, S Christian, Whelan, Emily R. , Rozen, Todd D , Farraye, Francis A , Cheung, Joseph , Grach, Stephanie L , Gajarawala, Shilpa , Munipalli, Bala , Shufelt, Chrisandra L , Knight, Dacre R T , Bruno, Katelyn A , Fairweather, DeLisa , Bhutani, Mira, Farraye, Francis A. , Soyer, Ozan, Grach, Stephanie L. , Shufelt, Chrisandra , Bruno, Katelyn A.

Mayo Clinic

Rheumatology Advances in Practice | December 10, 2024 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/rap/rkae134 | PMID 39660107 Get It

Abstract Objectives Patients with hypermobile Ehlers–Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) experience a wide array of symptoms and system disorders. This study aimed to identify whether differences occurred in 115 self-reported symptoms and comorbidities in patients diagnosed with hEDS or HSD. Methods In this study we analysed self-reported data from an EDS Clinic intake questionnaire in patients diagnosed with hEDS, HSD or no hypermobile conditions. Results From 1 November 2019 to 7 March 2024, the EDS Clinic saw 2088 patients. Using the 2017 diagnostic criteria, 66.5% were diagnosed with HSD (n = 1389), 20.3% with hEDS (n = 423), 10.6% with historic HSD (H-HSD) or localized HSD (L-HSD) (n = 256) (hypermobile controls) and 2.6% were not diagnosed with hEDS, HSD, H-HSD or L-HSD (n = 55) (controls). Symptoms/comorbidities that occurred with high prevalence in both hEDS and HSD included joint pain (hEDS 82.0%, HSD 88.9%), allergy (hEDS 77.0%, HSD 77.0%), subluxations (hEDS 71.2%, HSD 72.6%), brain fog (hEDS 70.0%, HSD 74.7%), headache (hEDS 68.1%, HSD 69.1%), anxiety (hEDS 60.3%, HSD 69.3%), depression (hEDS 52.2%, HSD 58.0%), migraine (hEDS 53.7%, HSD 52.5%), nausea (hEDS 54.6%, HSD 59.5%) and constipation (hEDS 53.0%, HSD 57.2%). In contrast, 9/115 (8%) symptoms/comorbidities were self-reported significantly more often in hEDS but 42/115 (37%) in HSD. hEDS patients reported more symptoms that suggest a defect in collagen, such as dislocation, hernias and rectal prolapse, while HSD patients reported more joint, muscle, allergy, neurological, gastrointestinal, sleep and psychological symptoms/comorbidities. Conclusion Although we found an overlap in some symptoms and comorbidities self-reported by hEDS/HSD patients, such as allergy/atopy, headache/migraine and gastrointestinal symptoms, our findings suggest key differences exist between the two diagnoses, suggesting that hEDS and HSD may be distinct conditions.
New findings regarding predictors of Poor Corporal Integrity in Penile Implant Recipients: A Multicenter International Invesigation
Chang, Chrystal , Barham, David W. , Dalimov, Zafardjan , Swerdloff, Daniel , Sadeghi‐Nejad, Hossein , Andrianne, Robert, Sempels, Maxime, Hsieh, Tung‐Chin , Hatzichristodoulou, Georgios , Hammad, Muhammed , Lentz, Aaron , Perito, Paul , Suarez‐Sarmiento, Alfredo, Hotaling, James M. , Gross, Kelli, Park, Sung Hun, Warner, Jonathan N. , Ziegelmann, Matthew , Modgil, Vaibhav , Jones, Adam , Pearce, Ian , Gross, Martin , Yafi, Faysal A. , Simhan, Jay , Miller, Jake , Jones, James M , Ziegelmann, Matthew , Yafi, Faysal A , Hammad, Muhammed A M , Osmonov, Daniar , Jones, James M. , Renterghem, Koenraad van , Burnett, Arthur L. “Bud”

Mayo Clinic

BJU International | December 10, 2024 | Volume: 135 | Issue: 3 | Pages: 528-534

10.1111/bju.16607 | PMID 39658322 Get It

Objectives To evaluate the pre‐ and intraoperative variables that impact the integrity of the corporal bodies over time after inflatable penile prosthesis (IPP) placement, as predictors of intraoperative corporal perforation and delayed cylinder complications have not been well characterized. Patients and Methods We retrospectively reviewed a 16‐centre multi‐institutional database of IPP surgeries performed by experienced implanters from 2016 to 2021. Poor corporal integrity (PCI) was defined as intraoperative (iPCI) corporal complications or postoperative (pPCI) corporal complications. Multivariable analysis was performed to identify independent predictors of PCI, iPCI, and pPCI. Primary outcomes included intra‐ and postoperative corporal complications. Results We identified 5153 patients for analysis from 5406 IPP cases, finding 152 (2.95%) cases of PCI. On multivariable analysis, predictors of PCI included revision IPP surgery (odds ratio [OR] 8.16, 95% confidence interval [CI] 5.15–12.92; P < 0.001), sequential dilatation (OR 2.12, 95% CI 1.32–3.39; P = 0.002), coronary artery disease (CAD)/peripheral vascular disease (PVD) (OR 1.81, 95% CI 1.18–2.77; P = 0.006), older age (OR 1.02, 95% CI 1.01–1.04; P = 0.013), and corporal scarring (OR 1.58, 95% CI 1.0–2.5; P = 0.049). Predictors of iPCI included revision IPP surgery (OR 7.34, 95% CI 4.18–12.88; P < 0.001), corporal scarring (OR 2.77, 95% CI 1.64–4.69; P < 0.001), radiation therapy (OR 2.25, 95% CI 1.0–5.04; P = 0.049), and older age (OR 1.03, 95% CI 1.0–1.05; P = 0.025). Revision IPP surgery (OR 7.92, 95% CI 3.69–17.01; P < 0.001), sequential dilatation (OR 3.4, 95% CI 1.61–7.19; P = 0.001), CAD/PVD (OR 2.98, 95% CI 1.56–5.72; P = 0.001), and history of priapism (OR 3.59, 95% CI 1.08–11.99; P = 0.038) were predictive of pPCI. Conclusion Coronary artery disease/PVD, being of older age, having corporal scarring, undergoing IPP revision surgery and sequential dilatation were predictive risk factors for complications associated with PCI. Identifying patients who are at risk of having PCI may improve patient‐specific counselling, consideration of referral to more experienced implanters, and surgical planning to potentially promote longer‐term device viability.
Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)
Sanford, Nina N. , Shi, Qian , Hein, David , Hall, William A. , Hein, David M , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 10, 2024 | Volume: 117 | Issue: 5 | Pages: 879-889

10.1093/jnci/djae313 | PMID 39656956 Get It

Abstract Background The National Clinical Trials Network (NCTN) is the largest government-sponsored organization in the United States; it is tasked with funding randomized controlled trials in oncology. It is unknown whether there are differences in study design by treatment modality. We evaluated differences in methodology between trials testing radiation therapy (RT) vs systemic therapy. Methods The Clinical Trials Support Unit website was used to identify active randomized controlled trials of systemic therapy or RT across NCTN cooperative groups through December 31, 2023. Studies in disease sites with more than 5 RT trials were included. Each trial’s protocol was reviewed to obtain key design information that was descriptively compared: primary endpoint, hypothesis testing type (superiority vs noninferiority), noninferiority margin, hypothesized effect size, power, and statistical significance level. Results A total of 186 randomized controlled trials (142 systemic therapy, 44 RT) were examined. Comparing primary endpoints, 59.1% vs 26.8% of RT vs systemic therapy trials, respectively, had a primary endpoint of overall survival. Nearly one-third (31.2%) of RT trials were noninferiority vs 6.3% of systemic therapy trials. Among breast cancer trials, 75% of RT studies were noninferiority vs 11.1% systemic therapy. Target effect size, power, and statistical significance level were similar by treatment modality within tumor types and disease settings. Conclusion Among NCTN cooperative group randomized controlled trials, there were marked differences in study design between RT vs systemic therapy trials. A higher benchmark for defining success for RT interventions was observed, with greater emphasis on overall survival as the primary endpoint. This finding may reflect differences in therapeutic mechanism by modality and types of study questions posed.
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
Haque, Tamanna , King, Zoe, Kishtagari, Ashwin , Madanat, Yazan F. , Borate, Uma , Slosky, David, Patnaik, Mrinal S., Bick, Alexander G., Verma, Amit , Jaiswal, Siddhartha , Kishtagari, Ashwin , Madanat, Yazan , Steensma, David P , Savona, Michael R , Jaiswal, Siddhartha , Shastri, Aditi , Desai, Pinkal , Xie, Zhuoer , Hammond, Danielle , Abaza, Yasmin , Silver, Alexander J. , Singh, Abhay , Heimlich, Jonathan Brett , Bolton, Kelly L. , Patnaik, Mrinal S., Bick, Alexander G. , Steensma, David P. , Savona, Michael R.

Mayo Clinic

British Journal of Haematology | December 10, 2024 | Volume: 206 | Issue: 2 | Pages: 416-427

10.1111/bjh.19925 | PMID 39653653 Get It

SummaryThe age‐associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH‐focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021.
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
Laetsch, Theodore W. , Voss, Stephan D. , Ludwig, Kathleen , Hall, David , Barkauskas, Donald A. , DuBois, Steven G. , Ronan, Joan, Rudzinski, Erin R. , Memken, Amanda , Robinson, Krystal, Sorger, Joel, Bhatla, Teena, Church, Alanna J. , Fox, Elizabeth , Weigel, Brenda J. , Voss, Stephan D , Reid, Joel M , Crompton, Brian D , Church, Alanna J , Fox, Elizabeth , Weigel, Brenda J , Teachey, David T , Reid, Joel M. , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | December 9, 2024 | Volume: 43 | Issue: 10 | Pages: 1188-1197

10.1200/jco-24-01854 | PMID 39652801 Get It

PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed NTRK fusion–positive solid tumors with response-adapted duration of therapy and local control. METHODS Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability. The primary end point was the objective response rate (ORR) within six cycles in patients with infantile fibrosarcoma (IFS); patients with other histologic diagnoses were analyzed in a separate cohort. Secondary objectives included event-free survival (EFS) and overall survival (OS). RESULTS Thirty-three patients were enrolled: 18 with IFS and 15 with other solid tumors. The ORR within six cycles was 94% (17/18; 95% adjusted CI, 72.7 to 98.6) among children with IFS and 60% (9/15; 95% CI, 32.3 to 83.7) among children with other solid tumors. Six percent (2/33; 95% CI, 0.7 to 22.2) patients developed progressive disease while on therapy. Two-year EFS and OS among these groups were 82.2% (95% CI, 54.3 to 93.9) and 93.8% (95% CI, 63.2 to 99.1) for IFS and 80% (95% CI, 50.0 to 93.1) and 93.3% (95% CI, 61.3 to 99.0) for other solid tumors, respectively. Patients undergoing surgical resection of their tumor had prolonged EFS, with only 1 of 16 such patients experiencing disease progression. Four of 33 patients had dose-limiting toxicities. CONCLUSION Larotrectinib is highly active in patients with newly diagnosed NTRK fusion–positive solid tumors. Larotrectinib should be a frontline option for patients with IFS and other NTRK fusion–positive solid tumors. Local control with surgical resection remains important in the treatment of patients with IFS.
Concordance and Test-Retest Consistency of Sleep Biomarker-Based Neurodegenerative Disorder Profiling
Levendowski, Daniel J. , Walsh, Christine M., Lee‐Iannotti, Joyce , Salat, David H. , Fischer, Corrine, Mazeika, Gandis, Tsuang, Debby W. , Chahine, Lana M. , Walsh, Christine M. , Berka, Chris , Boeve, Bradley F. , Ferini-Strambi, Luigi , Lewis, Simon J.G. , Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

No container title available | December 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5111150/v1 Get It

Abstract Biomarkers that aid in early detection of neurodegeneration are needed to enable early symptomatic treatment and enable identification of people who may benefit from neuroprotective interventions. Increasing evidence suggests that sleep biomarkers may be useful, given the bi-directional relationship between sleep and neurodegeneration and the prominence of sleep disturbances and altered sleep architectural characteristics in several neurodegenerative disorders. This study aimed to demonstrate that sleep can accurately characterize specific neurodegenerative disorders (NDD). A four-class machine-learning algorithm was trained using age and nine sleep biomarkers from patients with clinically-diagnosed manifest and prodromal NDDs, including Alzheimer’s disease dementia (AD = 27), Lewy body dementia (LBD = 18), and isolated REM sleep behavior disorder (iRBD = 15), as well as a control group (CG = 58). The algorithm was validated in a total of 381 recordings, which included the training data set plus an additional AD = 10, iRBD = 18, Parkinson disease without dementia (PD = 29), mild cognitive impairment (MCI = 78) and CG = 128. Test-retest consistency was then assessed in LBD = 10, AD = 9, and CG = 46. The agreement between the NDD profiles and their respective clinical diagnoses exceeded 75% for the AD, LBD, and CG, and improved when NDD participants classified Likely Normal with NDD indications consistent with their clinical diagnosis were considered. Profiles for iRBD, PD and MCI participants were consistent with the heterogeneity of disease severities, with the majority of overt disagreements explained by normal sleep characterization in 27% of iRBD, 21% of PD, and 26% of MCI participants. For test-retest assignments, the same or similar NDD profiles were obtained for 88% of LBD, 86% in AD, and 98% of CG participants. The potential utility for NDD subtyping based on sleep biomarkers demonstrates promise and requires further prospective development and validation in larger NDD cohorts.
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
Peterlin, B. Lee , Bond, Dale S. , Ferreira, Rosa De Abreu, Dabruzzo, Brett , Goadsby, Peter J. , Trugman, Joel M. , Dabruzzo, Brett , Goadsby, Peter J , Ailani, Jessica , Dodick, David W. , Liu, Yingyi , Smith, Jonathan H.

Mayo Clinic

Cephalalgia | December 9, 2024 | Volume: 44 | Issue: 12 | Pages: No page available

10.1177/03331024241299753 | PMID 39648629 Get It

Background Migraine is associated with obesity. These analyses evaluated weight change with atogepant used as a preventive migraine treatment. Methods Five atogepant clinical trials in adults with migraine (one phase 2b/3; four phase 3) were included: Three 12-week, randomized, placebo-controlled trials (episodic migraine: two; chronic migraine: one); one 40-week, open-label extension trial and one 52-week, standard care, randomized, long-term safety trial in episodic migraine. Change from baseline in body weight was measured. Results Mean baseline body mass indexes were 30.0–30.7 kg/m 2 (pooled episodic migraine [United States only]) and 25.0–25.5 kg/m 2 (chronic migraine [East Asia, Europe, and North America]). More participants treated with atogepant 60 mg once-daily compared to placebo experienced ≥7% weight loss at any time in the pooled episodic migraine placebo-controlled trials (4.9% vs. 2.8%), chronic migraine placebo-controlled trial (5.8% vs. 2.0%), and pooled open-label extension and long-term safety trials (24.0% vs.14.7% in standard care [long-term safety only]). In the placebo-controlled trials, weight loss with atogepant 60 mg once-daily was observed at week 2 (pooled episodic migraine: −0.32%; chronic migraine: −0.39%), increasing at week 12 (pooled episodic migraine: −1.02%; chronic migraine: −1.50%); compared to weight gain with placebo at week 12 (pooled episodic migraine: +0.49%; chronic migraine: +0.10%). In the long-term episodic migraine studies, weight loss with atogepant 60 mg once-daily was observed at week 4 (long-term safety: −0.42%; open-label extension: −0.76%), increasing at week 40 (long-term safety: −2.38%; open-label extension: −2.09%). Conclusion Atogepant was associated with modest dose- and duration-dependent weight loss. Trial registration ClinicalTrials.gov identifiers: NCT02848326 (CGP-MD-01); NCT03777059 (3101-301-002); NCT03700320 (long-term safety trial); NCT03939312 (open-label extension trial); NCT03855137 (3101-303-002).
Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis
Singh, Raj , Bowden, Greg , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Reda, Wael A. , Tawadros, Sameh R. , Eldin, Reem Emad, Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Hess, Judith, Templeton, Kelsey, Wei, Zhishuo , Pikis, Stylianos , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Lee, Cheng-chia, Niranjan, Ajay , Lunsford, L. Dade , Sheehan, Jason P. , Perlow, Haley K , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Palmer, Joshua D. , Elhamdani, Shahed, Nabeel, Ahmed M. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Mantziaris, Georgios , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | December 6, 2024 | Volume: 142 | Issue: 5 | Pages: 1357-1365

10.3171/2024.7.jns24920 | PMID 39642356 Get It

OBJECTIVE This study aimed to evaluate local control (LC) of tumors, patient overall survival (OS), and the safety of stereotactic radiosurgery (SRS) for esophageal cancer brain metastases (EBMs). METHODS This retrospective cohort study used data from 15 International Radiosurgery Research Foundation facilities encompassing 67 patients with 185 EBMs managed using SRS between January 2000 and May 2022. The median patient age was 63 years, with a male predominance (92.5%). Most patients (64.2%) had a single brain metastasis, while 7.5% had more than 5 metastases. The median tumor volume was 0.9 cm 3 , and the median margin dose delivered to the tumor was 20 Gy. RESULTS The median OS post-SRS was 15.2 months, with 1- and 2-year OS rates of 65.7% and 32.3%, respectively. A significant inverse correlation was found between the number of EBMs and OS in the univariable analysis. LC rates at 1 and 2 years were 89% and 76%, respectively. Adverse radiation effects (AREs) were observed in 17.9% of patients, with 13.4% being mild and transient and 4.5% severely symptomatic (Common Terminology Criteria for Adverse Events grade 3). New intracranial disease developed in 58.2% of patients, with 1- and 2-year rates of 58% and 73%, respectively. CONCLUSIONS SRS for EBMs demonstrated high survival rates and effective tumor control, with a low incidence of severe AREs. These findings highlight the potential role of SRS in the multidisciplinary multimodality management paradigm of EBM.